With COVID-19 variant threats rising, why are vaccine stocks falling?

Stock markets moved slightly higher despite general worries.

| More on:
health care worker giving a woman a COVID 19 vaccine

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The stock market has been choppy this week, and Wednesday brought some new fears to the table. Market participants are looking closely at rising incidence of new COVID-19 variants, which could threaten to bring yet another wave of cases to areas where vaccination rates have been less than ideal. By the end of the day, major market benchmarks like the Dow Jones Industrial Average (DJINDICES: ^DJI), S&P 500 (SNPINDEX: ^GSPC), and Nasdaq Composite (NASDAQINDEX: ^IXIC) had managed to recover their lost ground, but many investors remain nervous.
Index Percentage Change Point Change
Dow +0.30% +104
S&P 500 +0.34% +15
Nasdaq Composite +0.01% +1

Data source: Yahoo! Finance.

One thing that was somewhat surprising was the behavior of vaccine stocks amid worries about new COVID-19 variants. Moderna (NASDAQ: MRNA), BioNTech (NASDAQ: BNTX), and Novavax (NASDAQ: NVAX) were all sharply lower on the day. Below, we'll look more closely at the moves to try to figure out what's going on.

Big losses in the vaccine area

The declines in vaccine stocks  were quite substantial. BioNTech made out relatively well with a 4% decline. However, Moderna dropped almost 5% on the day, and Novavax was the hardest hit, falling 14%. Other vaccine hopefuls were also weaker, as Inovio Pharmaceuticals (NASDAQ: INO) dropped almost 7% and Ocugen (NASDAQ: OCGN) lost nearly 5%. Most analysts attributed the declines in vaccine stocks to the delta variant of COVID-19. The delta variant is much more contagious than earlier variants, and it has become the most prevalent cause of COVID-19 in the U.S. recently. The Centers for Disease Control and Prevention recently estimated that slightly over half of U.S. COVID-19 cases are now coming from the delta variant. The reason for concern seems to stem from the possibility that as COVID-19 variants evolve, they'll eventually get to the point at which current versions of vaccines are no longer effective. At least based on preliminary data, that doesn't seem to be the case with the delta variant. Existing vaccines from Moderna and BioNTech offer protection against the delta variant, albeit with some indications that efficacy might be somewhat reduced compared to earlier variants.

Opportunity abounds

However, declines in vaccine stocks make little sense in light of ongoing worries about COVID-19. The reasons are simple. First, greater awareness of the importance of vaccination to fight future variant mutations should boost sales of currently available vaccines from these companies. But even more importantly, investors seem to assume that vaccine producers are standing still. Just as the virus can adapt to changing conditions, companies fighting the virus can adapt to the mutations, looking at ways to improve on existing vaccines. That might involve offering booster shots to those who've already received vaccinations, or it could eventually lead to entirely different vaccination regimens that could prove effective in fighting more aggressive strains of the virus. Sales of those new and existing products could actually help boost vaccine producers' longer-term prospects. With much of the world only now getting their chance to obtain and distribute vaccines to their populations, nervousness about vaccine stocks seems premature at best. If weakness continues, it'll be hard not to see lower prices for shares of vaccine makers as an opportunity for investors to take advantage of what in hindsight might well look like a bargain.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Should you invest $1,000 in Biontech Se right now?

Before you buy Biontech Se shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Biontech Se wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Happy family watching Netflix together.
International Stock News

Netflix stock gained 21.4% last month. Here's how.

Is Netflix on track for a long blockbuster run? Check out what's fuelling investor excitement about the media-streaming veteran right…

Read more »

An elderly man finds out he's made a mistake.
International Stock News

Warren Buffett's career in review: His worst investment decisions

Despite the wins, Buffett has also made plenty of errors in his long career.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
International Stock News

Warren Buffett's career in review: His best investment decisions

Buffett's best buys are simply astonishing.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Meta Platforms is ramping up data center and AI investments. Is the growth stock a buy now?

Let's take a look.

Read more »

A head shot of legendary investor Warren Buffett speaking into a microphone at an event.
International Stock News

Berkshire Hathaway stock plunges after Warren Buffett steps down. Is this a golden opportunity to buy?

Investors might be wondering whether they should be buying or selling Berkshire Hathaway stock now.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
International Stock News

Where Will Alphabet Be in 5 Years?

Today, the lowest-valued stock in the "Magnificent Seven" is Alphabet, and it's not close.

Read more »

Silhouette of CEO standing in conference room looking out at cityscape.
International Stock News

Who is Warren Buffett's successor Greg Abel?

Buffett's successor has been in training for years.

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop.
International Stock News

Do Google's antitrust woes make Alphabet stock a buy, sell, or hold?

In the past year, Google lost two major antitrust cases aimed at the heart of its business.

Read more »